Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Orv Hetil ; 162(32): 1297-1302, 2021 08 08.
Artigo em Húngaro | MEDLINE | ID: mdl-34370689

RESUMO

Összefoglaló. Bevezetés: A krónikus myeloid leukaemia a diagnosztika fejlodésének és a tirozin-kináz-gátlók bevezetésének köszönhetoen az elmúlt évtizedekben kiváló prognózisú betegséggé vált. Célkituzés: A betegséggel kapcsolatos ismereteink nagy része klinikai vizsgálatokból származik, emiatt kiemelt szerepük van a nem szelektált beteganyagon végzett elemzéseknek. Módszer: Retrospektív elemzésünkben a Semmelweis Egyetem Belgyógyászati és Onkológiai Klinikáján 2003 és 2019 között tirozin-kináz-gátló kezelésben részesült betegek adatait tekintettük át. Eredmények: Klinikánkon összesen 88 beteg részesült terápiában, közülük 73 beteg az analízis idopontjában is kezelés alatt állt. A betegek 5 éves össztúlélése 86%, 5 éves progressziómentes túlélése 70% volt. 9 beteg halt meg, közülük 2 betegnél a halál oka a progrediáló alapbetegség volt. 38 betegnél volt szükség az elso vonalban terápiaváltásra, a váltás oka akkor elsosorban az elégtelen terápiás válasz volt. A késobbi terápiaváltásokra elsosorban intolerancia miatt került sor. Az elso vonalban a betegek több mint fele major molekuláris választ ért el, a jelenlegi kezelés mellett a betegek 85%-ánál major molekuláris választ detektáltunk. Megbeszélés: Adataink alapján az intézményünkben kezelt betegek túlélése és a betegek által elért terápiás válasz megfelel a nemzetközi adatoknak. Következtetés: Mivel nem válogatott beteganyagról van szó, a kapott eredmények pontosabb képet adhatnak a krónikus myeloid leukaemia tirozin-kináz-gátlóval történt kezelésének eredményeirol. Orv Hetil. 2021; 162(32): 1297-1302. INTRODUCTION: As a result of advances in diagnostic techniques and the introduction of tyrosine kinase inhibitors, the prognosis of chronic myeloid leukemia has improved over the last decades. OBJECTIVE: Most of our knowledge about chronic myeloid leukemia results from clinical trials, therefore data derived from non-selected patient population is substantial. METHOD: Data of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors at the Department of Internal Medicine and Oncology, Semmelweis University, between 2003 and 2019 were analysed retrospectively. RESULTS: 88 patients received treatment, 73 patients were on therapy at the time of the analysis. Overall survival at 5 years was 86%, progression-free survival at 5 years was 70%. 9 patients died, 2 of them due to progressive disease. 38 patients needed 2nd line therapy, the main reason of treatment change was failure of therapy. Subsequent treatment modifications were conducted mostly because of intolerance. More than half of the patients on 1st line treatment reached major molecular response and 85% of the patients on treatment at the end of the analysis are in major molecular response. DISCUSSION: Based on our data, survival and therapeutic response of patients in our center are similar to the international results. CONCLUSION: This analysis provides real-world data about treatment results of chronic myeloid leukemia in the tyrosine kinase inhibitor era. Orv Hetil. 2021; 162(32): 1297-1302.


Assuntos
Leucemia Mielogênica Crônica BCR-ABL Positiva , Leucemia Mieloide , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Estudos Retrospectivos , Resultado do Tratamento , Universidades
2.
Pathol Oncol Res ; 25(2): 535-540, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30361908

RESUMO

Chronic lymphocytic leukemia (CLL) is one of the most common haematological malignancies exhibiting remarkable heterogeneity in clinical course. Rituximab added to standard chemotherapy has been proven to increase response rate and eventually survival among previously untreated CLL patients. CILI was an open-label, non-randomized, single arm, multicentric, observational study aimed to collect real-life effectiveness data for rituximab used according to the current label in combination with standard chemotherapy in previously untreated CLL patients. Overall response rates (ORR) in the entire study population as well as in various subgroups were estimated. Adverse events were recorded during the entire course of the study. A total number of 150 patients were enrolled by 15 Hungarian study sites. Out of these, 82 patients received 6 cycles of rituximab containing treatment. Overall response rates of 88.24% (CI95%: 81.6-93.12%) and 94.59% (CI95%: 86.73-98.51%) were recorded in the intent-to-treat (ITT) and per-protocol (PP) populations, respectively. In both study populations, somewhat higher ORR was observed in patients aged ≥65 years. Subgroups defined according to either chromosomal aberrations (presence of 11q and 17p deletions) showed apparently high ORRs, though these rates were most probably biased by low patient numbers. 144 adverse events were reported during the study, of which 15 AEs were considered to be related to the administration of rituximab. Analyses of the efficacy variables have revealed comparable results to those previously reported by controlled clinical trials.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Rituximab/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Rituximab/efeitos adversos , Resultado do Tratamento
3.
Magy Onkol ; 61(1): 29-35, 2017 Mar 08.
Artigo em Húngaro | MEDLINE | ID: mdl-28273186

RESUMO

Advances in the treatment of acute myeloid leukaemia are still modest. Through emerging knowledge in molecular genetics we gain new insights into the pathogenesis of the disease. The first targeted therapies have emerged, but failed to show a breakthrough effect. The outcome of standard chemotherapy has improved due to improvements in supportive care and slight modifications in the protocols, but we still hope to augment the results of intensive chemotherapy applied in our young and fit patients, by adding targeted therapeutic agents. Possibilities of old and frail patients were even less: they could only receive cytotoxic agents with low efficacy but severe side effects. This group of patients can already benefit from new therapies, like hypomethylating agents. The review summarizes current approved therapies and gives insight into ongoing development of new agents, which will hopefully enrich our therapeutic possibilities in the near future.


Assuntos
Leucemia Mieloide Aguda/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica , Terapia Combinada , Humanos , Terapia de Alvo Molecular
4.
Magy Onkol ; 61(1): 67-74, 2017 Mar 08.
Artigo em Húngaro | MEDLINE | ID: mdl-28273190

RESUMO

The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.


Assuntos
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Leucemia Mielogênica Crônica BCR-ABL Positiva/enzimologia , Inibidores de Proteínas Quinases/uso terapêutico , Proteínas Tirosina Quinases/antagonistas & inibidores , Humanos , Medição de Risco
5.
Magy Onkol ; 60(2): 137-44, 2016 06 06.
Artigo em Húngaro | MEDLINE | ID: mdl-27275640

RESUMO

Differential diagnosis of hairy cell leukemia (HCL) and related disorders (hairy cell leukemia variant and splenic marginal zone lymphoma) is of utmost importance since the treatment and prognosis of these lymphomas differ. Since 2011 diagnosis of hairy cell leukemia has been easier because of discovery of the disease defining somatic mutation BRAF V600E mutation, which has been also known as driver mutation in malignant melanoma. The presence of this mutation enabled targeted molecular therapy in HCL as well. As first line therapy purine nucleoside analogues are the gold standard, but refractory/relapsed patient are candidates for targeted BRAF-inhibitor therapy. This manuscript serves as guidance in making diagnosis and standard treatment of HCL, and summarizes newest data about molecular therapy, including our single center experience collected from 75 patients.


Assuntos
Leucemia de Células Pilosas/diagnóstico , Leucemia de Células Pilosas/terapia , Mutação , Diagnóstico Diferencial , Marcadores Genéticos/genética , Humanos , Leucemia de Células Pilosas/genética , Melanoma , Mutação/genética , Proteínas de Neoplasias/antagonistas & inibidores , Proteínas de Neoplasias/genética , Proteínas Proto-Oncogênicas B-raf
6.
Biochem Biophys Res Commun ; 410(3): 682-7, 2011 Jul 08.
Artigo em Inglês | MEDLINE | ID: mdl-21699885

RESUMO

We have previously reported the in vitro anti-proliferative effect of 4-thio-uridylate (s(4)UMP) on OCM-1 uveal melanoma cells. Here, we assessed the efficacy of s(4)UMP on JY cells. Treatment of JY cells with s(4)UMP suppressed their colony forming activity and induced apoptosis; healthy human bone marrow granulocyte-macrophage progenitor cells were 14-fold less sensitive to the nucleotide. In vivo effectiveness of s(4)UMP was determined using xenograft SCID mouse model. s(4)UMP decreased the cell number and colony forming activity of the total cell content of the femur of SCID mice transplanted with JY cells without affecting the bone marrow of healthy mice. These results suggest that s(4)UMP alone or in combination with other clinically approved anti-leukemic remedies should be further explored as a potential novel therapeutic agent.


Assuntos
Antineoplásicos/uso terapêutico , Leucemia de Células B/tratamento farmacológico , Tionucleotídeos/uso terapêutico , Uridina Monofosfato/análogos & derivados , Animais , Antineoplásicos/química , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Humanos , Camundongos , Camundongos SCID , Células-Tronco/efeitos dos fármacos , Tionucleotídeos/química , Tionucleotídeos/farmacocinética , Uridina Monofosfato/química , Uridina Monofosfato/farmacocinética , Uridina Monofosfato/uso terapêutico , Ensaios Antitumorais Modelo de Xenoenxerto
7.
Pathol Oncol Res ; 13(3): 237-42, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17922053

RESUMO

The composition of reactive cell populations, which constitute the majority of tumor load in Hodgkin's lymphoma (HL), can influence the prognosis of the disease. Besides widely accepted and applied prognostic scores, the authors evaluate biological factors that may have a prognostic impact. Previous data indicate that the rate of eosinophils and mast cells in the reactive cell population, determined already at diagnosis, can be used for this purpose. Histological samples from 104 patients with HL with an average follow-up period of 110 (24-214) months were retrospectively analyzed. Mast cell positivity was associated with better overall survival, although this difference was only of borderline statistical significance (p=0.092). No significant difference was found in parameters like overall survival (OS, p=0.906) or event-free survival (EFS, p=0.307) of eosinophil-positive vs. -negative cases or in EFS (p=0.742) of mast cell-positive vs. -negative individuals (criterion for a positive specimen was more than 5% of appropriate cells in the reactive cell population). Looking at the effect of eosinophilia and mastocytosis together, there was no significant difference between the subgroups categorized according to the combined presence of the two cell types. It seems that tissue eosinophil and mast cell predominance have no prognostic value that could be used in clinical practice, although a tendency for correlation of mast cell positivity with overall survival could be seen. For a definitive statement, multicenter studies should be performed involving a higher number of patients suffering from HL.


Assuntos
Eosinófilos/patologia , Doença de Hodgkin/patologia , Mastócitos/patologia , Adolescente , Adulto , Idoso , Criança , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Estudos Retrospectivos
8.
J Cell Sci ; 119(Pt 13): 2797-806, 2006 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-16772337

RESUMO

The involvement of telomerase in cellular immortalization and senescence has often been assessed by means of telomerase expression at the RNA level and quantification of telomerase activity by the telomeric repeat amplification protocol assay. However, these methods either neglected the existence of various telomerase splice variants, or ignored the nonconventional functions of telomerase independent of its ability to elongate and maintain telomere length. Immunodetection of telomerase is now being recognized as a necessary approach to precisely elucidate its roles in oncogenesis and senescence. A few antibodies directed against the catalytic subunit of the human telomerase (hTERT) are currently used but their specificity is not always demonstrated. A survey of the literature showed inconsistencies and led us to comparatively re-evaluate the most frequently used antibodies. Surprisingly, mass spectrometry, two-dimensional gel analysis and immunofluorescent experiments revealed that the most frequently used hTERT immunoprobe, a mouse monoclonal antibody that was claimed to be directed against an hTERT protein epitope, in fact recognizes nucleolin rather than telomerase. Our findings have interesting implications regarding the biology of nucleolin and telomerase in the context of pathophysiological investigations recently carried out.


Assuntos
Proteínas de Ligação a DNA/análise , Fosfoproteínas/análise , Proteínas de Ligação a RNA/análise , Telomerase/análise , Anticorpos/metabolismo , Especificidade de Anticorpos , Diferenciação Celular , Células Cultivadas , Reações Cruzadas , Proteínas de Ligação a DNA/deficiência , Eletroforese em Gel Bidimensional , Eletroforese em Gel de Poliacrilamida , Imunofluorescência , Perfilação da Expressão Gênica , Células HeLa , Humanos , Imunoprecipitação , Espectrometria de Massas , Mapeamento de Peptídeos , RNA Mensageiro/metabolismo , Telomerase/deficiência , Nucleolina
9.
FEBS Lett ; 579(6): 1411-6, 2005 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-15733850

RESUMO

Most tumor cells attain their immortality by reactivating telomerase. We report here the telomerase inhibitory potential of chimeric oligonucleotides composed of a 13mer antisense sequence targeting the telomerase RNA template region and a (s4dU)n moiety at its 3' or 5'-end. The increase of the thiolated chain length enhances the telomerase inhibitory potential, but decreases specificity, indicated by HIV reverse transcriptase inhibition. Chimeras with 5' (s4dU)(n)s were more potent inhibitors than the antisense alone or the 3' modified ones. Cy5-labeled (s4dU)4AS and (s4dU)8AS proved the internalization of the oligonucleotides, raising the possibility to be tested as cellular anti-telomerase agents.


Assuntos
Oligonucleotídeos Antissenso/química , Oligonucleotídeos Antissenso/farmacologia , Telomerase/antagonistas & inibidores , Sequência de Bases , Linhagem Celular Tumoral , Inibidores Enzimáticos/química , Inibidores Enzimáticos/metabolismo , Inibidores Enzimáticos/farmacologia , HIV/enzimologia , Humanos , Concentração Inibidora 50 , Estrutura Molecular , Oligonucleotídeos Antissenso/genética , Oligonucleotídeos Antissenso/metabolismo , DNA Polimerase Dirigida por RNA/metabolismo , Telomerase/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA